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Original Investigation | Substance Use and Addiction

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk
Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
Carrie M. Mintz, MD; Kevin Y. Xu, MD, MPH; Ned J. Presnall, MSW; Sarah M. Hartz, MD, PhD; Frances R. Levin, MD; Jeffrey F. Scherrer, PhD;
Laura J. Bierut, MD; Richard A. Grucza, PhD

Abstract
IMPORTANCE Stimulant medication use is common among individuals receiving buprenorphine for
opioid use disorder (OUD). Associations between prescription stimulant use and treatment
outcomes in this population have been understudied.

Key Points
Question How are use of prescription
stimulants associated with treatment
outcomes in persons with opioid use
disorder (OUD)?

OBJECTIVES To investigate whether use of prescription stimulants was associated with (1) drug-

Findings In this cohort study of 22 946

related poisoning and (2) buprenorphine treatment retention.

persons with OUD receiving
buprenorphine treatment, stimulant

DESIGN, SETTING, AND PARTICIPANTS This retrospective, recurrent-event cohort study with a

treatment days were associated with

case-crossover design used a secondary analysis of administrative claims data from IBM MarketScan

19% increased odds of drug-related

Commercial and Multi-State Medicaid databases from January 1, 2006, to December 31, 2016.

poisoning and 36% decreased risk of

Primary analyses were conducted from March 1 through August 31, 2021. Individuals aged 12 to 64

attrition from buprenorphine treatment.

years with an OUD diagnosis and prescribed buprenorphine who experienced at least 1 drug-related
poisoning were included in the analysis. Unit of observation was the person-day.

Meaning These findings suggest that
among persons with OUD who have
experienced a drug-related poisoning,

EXPOSURES Days of active stimulant prescriptions.

stimulant use is associated with a
modest increased risk of drug-related

MAIN OUTCOMES AND MEASURES Primary outcomes were drug-related poisoning and
buprenorphine treatment retention. Drug-related poisonings were defined using International
Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision, codes; treatment retention was defined by continuous

poisoning that may be offset by longer
duration of buprenorphine treatment,
which is associated with protection
against overdose.

treatment claims until a 45-day gap was observed.
RESULTS There were 13 778 567 person-days of observation time among 22 946 individuals (mean
[SD] age, 32.8 [11.8] years; 50.3% men) who experienced a drug-related poisoning. Stimulant
treatment days were associated with 19% increased odds of drug-related poisoning (odds ratio [OR],
1.19 [95% CI, 1.06-1.34]) compared with nontreatment days; buprenorphine treatment days were

+ Invited Commentary
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

associated with 38% decreased odds of poisoning (OR, 0.62 [95% CI, 0.59-0.65]). There were no
significant interaction effects between use of stimulants and buprenorphine. Stimulant treatment
days were associated with decreased odds of attrition from buprenorphine treatment (OR, 0.64
[95% CI, 0.59-0.70]), indicating that stimulants were associated with 36% longer mean exposure to
buprenorphine and its concomitant protection.
CONCLUSIONS AND RELEVANCE Among persons with OUD, use of prescription stimulants was
associated with a modest increase in per-day risk of drug-related poisoning, but this risk was offset
by the association between stimulant use and improved retention to buprenorphine treatment,
which is associated with protection against overdose.
JAMA Network Open. 2022;5(5):e2211634. doi:10.1001/jamanetworkopen.2022.11634
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Introduction
Now in its third decade, the current opioid epidemic has claimed an unprecedented number of US
lives: More than 500 000 persons have died due to opioid-related overdoses since 1999.1,2 Although
opioid use disorder (OUD) confers elevated risks of morbidity and mortality,3-6 persons with OUD
frequently have co-occurring conditions that may increase these risks even further. For example,
attention-deficit/hyperactivity disorder (ADHD) is estimated to occur in 20% to 25% of persons in
who seek treatment for OUD,7-9 and co-occurring ADHD portents worse substance use disorder
(SUD)–related outcomes, including lower prevalence of SUD treatment participation10 and higher
rates of treatment attrition.11 Depression is also common among persons with OUD: As many as 48%
of persons with OUD have met criteria for a lifetime major depressive episode,12 and persons with
OUD have an elevated risk of suicide.3,13 Finally, persons with OUD have become increasingly likely to
use psychostimulants—particularly methamphetamine—over time, perhaps to combat the sedating
effects of increasingly potent illicitly made opioids such as fentanyl.14 For example, the percentage of
persons in OUD treatment who also reported using methamphetamine increased from 2% to almost
13% from 2008 to 2017.15 Disturbingly, the number of overdose deaths involving both opioids and
stimulants has increased dramatically in recent years,16-18 and fatalities due to this coingestion are
often referred to as the “fourth wave” of the opioid epidemic.19 Thus, identifying optimal treatments
for these particularly high-risk subgroups of persons with OUD is critical to help prevent subsequent
opioid-related deaths.
Medication treatment is considered standard of care for OUD.20 Of the 3 medications approved
by the US Food and Drug Administration for OUD, buprenorphine, a partial opioid agonist, is most
commonly prescribed21,22 and has been repeatedly shown to be effective for relapse prevention23,24
and to be associated with decreased risk of overdose and death.4,25-28
Centrally acting stimulants carry US Food and Drug Administration approval for ADHD
treatment in both children and adults and are considered first-line treatments for ADHD in these
populations.29,30 In addition to ADHD, stimulants are commonly used off-label to treat other
conditions, including depression and stimulant use disorders.31 In fact, as many as 50% of stimulant
prescriptions may be written for off-label conditions in adults,32,33 and the prevalence of stimulant
prescriptions has increased over time, particularly among adults.34
Because stimulants carry the potential for misuse,35-37 clinicians may be reluctant to prescribe
them to persons with co-occurring SUD owing to concern that the stimulants may increase the risk of
SUD relapse.38 Although existing data to provide definitive guidance on this issue are lacking,39 a
2017 study using insurance claims data found that stimulant prescriptions were associated with
decreased risk of emergency department visits related to substance use among persons with an SUD
diagnosis.40 Further, several randomized clinical trials have examined stimulant use in adults with
co-occurring stimulant use disorder and ADHD and found either a lack of association between
stimulant prescriptions and illicit drug use41 or a protective effect.42,43
Outcomes among persons who are prescribed stimulants and have co-occurring OUD, however,
are particularly understudied. We know of only 2 prior studies44,45 that have examined stimulant use
in populations with OUD. Both studies focused on persons in methadone maintenance programs
who had co-occurring ADHD diagnoses and were treated with stimulants, and neither study found an
association between stimulant use and illicit drug use risk,44,45 although generalizability of results is
limited by strict inclusion criteria, small sample sizes, and short follow-up periods. We know of no
previous studies that have examined associations between stimulant use and SUD-related outcomes
in persons with OUD treated with buprenorphine.
In addition to illicit drug use, treatment retention is increasingly considered a clinically
meaningful outcome in SUD research.46,47 For persons with OUD, longer treatment retention has
been associated with lower overdose risk.25 Recent evidence indicates that stimulant treatment may
improve SUD treatment retention among persons with co-occurring SUD and ADHD48; thus,
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whether prescription stimulant use is associated with improved buprenorphine treatment retention
in persons with OUD is an important clinical question.
Observational cohort studies may be particularly helpful for addressing questions about
prescription stimulant medication use and OUD outcomes given their allowance for large sample
sizes, real-world populations, and potential for relatively long follow-up periods. Thus, in this study,
we used large insurance claims databases including persons with OUD receiving buprenorphine
treatment and a case-crossover analytical design to examine associations between prescription
stimulant use and 2 clinically relevant OUD-related outcomes: (1) drug-related poisonings and (2)
buprenorphine treatment retention.

Methods
Data Source
This cohort study with a case-crossover design accessed IBM MarketScan Commercial and MultiState Medicaid databases, which included information from January 1, 2006, to December 31, 2016,
on use of health care resources, expenditures, and prescription pharmacy files across both
employer-sponsored and Medicaid health plans. Analyses were conducted from March 1 through
August 31, 2021. Data were deidentified, thus the study was exempted from human subjects review
and informed consent by the Washington University in St Louis institutional review board. The study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline.

Participants
The analytical sample included individuals with OUD aged 12 to 64 years who (1) received a
buprenorphine prescription for longer than 1 day and (2) experienced at least 1 drug-related
poisoning episode during insurance enrollment. Persons who met inclusion criteria but were not
prescribed stimulants were included in analyses to inform covariate estimates. For similar reasons,
we included persons who received buprenorphine at some point during their insurance coverage but
not necessarily during the study observation period. For buprenorphine treatment retention
analyses, because the purpose was to evaluate maintenance OUD treatment outcomes, we excluded
the small number of individuals who received buprenorphine only in the setting of detoxification
services. Figure 1 depicts the selection of the analytical sample. Additional details regarding
derivation of the cohort can be found elsewhere.22,49-51

Design
We conducted a within-person, repeated-event cohort study with a case-crossover design. Primary
units of observation were person-days. Each person-day was characterized by receipt or absence of a
stimulant prescription. For our first objective, case periods represented days on which a drugrelated poisoning occurred and were coded as 1; control periods were days when poisonings did not
occur and were coded as 0. Information about each participant’s exposure to medication during case
periods was compared with the same individual’s exposure distribution during control periods.52 An
individual’s first observed poisoning event served as the index event, and individuals could be
observed for as long as 1 year before and 1 year after this event. We chose a 2-year maximum
observation period because this was the mean duration of time participants were in the data set.
Participants could experience multiple drug-related poisonings as long as they occurred in the year
after the index event; observations in the year before the index event were used to improve covariate
estimates. Individuals who lost insurance coverage during the observation window were censored.
For our second objective, the case day was the last day of the buprenorphine treatment episode
and was coded as 1; all other days constituted control days and were coded as 0. Treatment days
were characterized by the presence or absence of stimulant prescription. There was no maximum
observation time imposed for retention analyses, but observation was limited to days within the
JAMA Network Open. 2022;5(5):e2211634. doi:10.1001/jamanetworkopen.2022.11634 (Reprinted)
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treatment episode. Individuals who lost insurance coverage during a treatment episode and those
who were retained in treatment throughout the duration of their enrollment were censored.

Primary Outcomes
Our first primary outcome was drug-related poisoning. We defined this outcome as any emergency
department visit or inpatient hospitalization involving International Classification of Diseases, Ninth
Revision, or International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision, codes for a drug-related poisoning. Methods for identifying these claims have been
described previously,50,51 and diagnostic classifications are provided in the eTable in the Supplement.
Our second primary outcome was buprenorphine treatment retention. We defined treatment
retention as described previously22,49: namely, continuous periods of time characterized by receipt
of buprenorphine, counseling, or both. We defined treatment episodes by first utilization of
buprenorphine or psychosocial treatment and continuing until a gap of at least 45 days without
claims for either psychosocial treatment or buprenorphine was encountered. Individuals were
permitted to undergo multiple treatment episodes.
Buprenorphine prescriptions were defined using National Drug Codes.22,49-51 We assumed an
active prescription connoted medication consumption. For example, if a participant received a
30-day prescription for buprenorphine, they were assumed to have taken buprenorphine for each of
the 30 days for which the prescription was written. To test whether buprenorphine treatment
episodes were valid proxies for buprenorphine exposure, we evaluated the percentage of days
during a treatment episode after initiating buprenorphine as evidenced by buprenorphine
prescriptions and days of supply: 84% of buprenorphine treatment episode days were covered by a
buprenorphine prescription, providing support that the treatment episode construct was a valid
approximation for buprenorphine exposure. Psychosocial treatment claims were defined using
Current Procedural Terminology codes.22,49

Ascertainment of Exposures
Our exposure variable comprised stimulant treatment days. Stimulant prescriptions were identified
using generic drug names that included the following words: amphetamine, methylphenidate, or
lisdexamfetamine. Because we were interested in the associations between our outcomes and

Figure 1. Development of Study Sample
304 676 Individuals 12 y and older with a diagnosis
of opioid use disorder in the MarketScan
commercially insured (2006-2016) and
Medicaid (2011-2016) databases who had
prescription drug coverage and ≥1 opioid
use disorder treatment claim during period
of insurance enrollment
237 789 Individuals excluded without drug-related
poisonings during insurance enrollment
66 887 Individuals who had ≥1 drug-related
poisoning claim during period of enrollment
42 514 Individuals excluded who did not receive
buprenorphine during insurance enrollment
24 373 Individuals who had drug-related poisonings
and were taking buprenorphine
1427 Individuals excluded who did not have fills
for stimulants on at least 80% of days
22 946 Individuals who had drug-related poisonings
and were taking buprenorphine during
insurance enrollment included in the
analytic sample for drug-related poisoning

22 791 Individuals who had drug-related poisoning
and received buprenorphine for maintenance
treatment included in the analytic sample
for buprenorphine retention

155 Individuals excluded who received
buprenorphine only in the setting of
detoxification services
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stimulants prescribed as maintenance treatment, we excluded persons for whom the mean ratio of
stimulant days supplied to days between fills was less than 0.8.

Covariates
Because each individual serves as their own control in a case-crossover design, time-invariant
covariates (eg, demographic information, SUD and non-SUD comorbidities) were not included as
covariates. We extracted data on age, sex, race and ethnicity (available in the Medicaid data set only),
insurance status, and comorbidities for descriptive purposes.
The repeated-event design allowed us to incorporate time as a covariate.52-54 We also included
benzodiazepines and statins as time-varying covariates in our model estimating drug-related
poisoning risk. Benzodiazepines were included given their high prevalence of use in populations with
SUD and prior work50 demonstrating a statistical interaction between benzodiazepine and
buprenorphine exposure when estimating risk for drug-related poisoning. Statins were included in a
negative control to evaluate whether our inclusion of time as a covariate was adequate to control
for persistent user bias.50,55 We included statins as a covariate in our model estimating
buprenorphine treatment retention to examine the degree to which healthy adherer bias56—that is,
that persons who are engaged in treatment for one condition are more likely to engage in treatment
for all conditions—might influence any association between stimulants and retention.

Statistical Analysis
Analyses were conducted using SAS, version 9.4 (SAS Institute Inc). We used a fixed-effect
conditional logit model to estimate the risk of drug-related poisoning events as a function of
stimulant exposure while controlling for secular time trends and time from index drug-related event
using restricted cubic splines. Effect sizes were measured as odds ratios (ORs) that, given the rarity
of the primary outcomes, were essentially equal to risk ratios.
We conducted several secondary analyses. First, because both the potency of misused opioids
and the number of opioid-related deaths have increased with time,1,18 we stratified the sample into 2
periods to examine whether estimates differed by time. We identified the median date within the
data set, rounded that date to the nearest calendar month, then estimated drug-related poisoning
risk for the first and second halves of the study period. Second, because stimulants are more
commonly prescribed for off-label reasons in adult populations,32 we stratified our sample by age
(12-29 and 30-64 years) to determine whether estimates differed by age group. Finally, we estimated
the association between stimulants and drug-related poisoning risk in persons who were prescribed
stimulants during their insurance enrollment to evaluate whether results were similar to those
obtained for the primary analytical sample. For buprenorphine treatment retention, we used a fixedeffect conditional logit model to estimate risk of a treatment attrition event (the last date of
retention) as a function of stimulant exposure during the treatment episode.

Results
Sample Characteristics
As shown in Table 1, the analytical sample for drug-related poisoning analyses consisted of 22 946
persons. A total of 11 393 women (49.7%) and 11 553 men (50.3%) were included. The mean (SD) age
was 32.8 (11.8) years. A total of 8169 patients (35.6%) had Medicaid insurance. In regard to
co-occurring diagnoses, 1154 patients (5.0%) had ADHD, 4383 (19.1%) had a major depressive
disorder, and 2553 (11.1%) had a stimulant use disorder in the 6 months before the first OUD
treatment claim. A total of 16 180 persons (70.5%) received buprenorphine during the year before or
after the index drug-related poisoning event, and 2470 (10.8%) received at least 1 stimulant
prescription during this time. The mean (SD) observation time was 600 (145) days.
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Stimulant Medication and Drug-Related Poisoning Risk
Table 2 presents the odds of drug-related poisoning as a function of medication. Stimulant treatment
days were associated with a 19% increased odds of drug-related poisoning relative to no treatment
(OR, 1.19 [95% CI 1.06-1.34]). As expected, buprenorphine treatment days were associated with a
38% decreased risk of drug-related poisoning relative to no treatment (OR, 0.62 [95% CI,
0.59-0.65]). There were no interactions observed (ie, the effects of stimulants were independent of
buprenorphine treatment and vice versa). As anticipated,50 benzodiazepines were associated with
increased risk of drug-related poisoning (OR, 1.93 [95% CI, 1.84-2.03]); statins were not associated
with drug-related poisoning risk (OR, 0.99 [95% CI, 0.86-1.13]). Results from secondary analyses
showed similar results, albeit with wider 95% CIs.

Stimulant Medication and Buprenorphine Treatment Retention
In total, 22 791 persons and 7 940 667 person-days were included in retention analyses. Stimulant
treatment days were associated with 36% decreased odds of buprenorphine treatment attrition (OR,

Table 1. Demographic Characteristics of Persons With Opioid Use
Disorder Prescribed Buprenorphine During Insurance Enrollment Who
Experienced a Drug-Related Poisoning
Characteristic

Patient data
(N = 22 946)a

Sex
Men

11 553 (50.3)

Women

11 393 (49.7)

Insurance
Commercial

14 777 (64.4)

Medicaid

8169 (35.6)

Race and ethnicityb
Black

436 (5.6)

Hispanic

88 (1.1)

White

6098 (78.6)

Other
Age, mean (SD), y

1135 (14.6)
32.8 (11.8)

Co-occurring SUD
Stimulantc

2553 (11.1)

Alcohol

3562 (15.5)

Sedative

2317 (10.1)

Co-occurring non-SUD psychiatric disorder
Major depressive disorder

4383 (19.1)

Anxiety disorder

8745 (38.1)

Psychotic disorder

901 (3.9)

ADHD

1154 (5.0)

Medication prescription during year before and after
index drug-related poisoning
Buprenorphine

16 180 (70.5)

Stimulant

2470 (10.8)

Benzodiazepine

13 210 (57.6)

Statin

1674 (7.3)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; SUD, substance
use disorder.
a

Unless otherwise indicated, data are expressed as number (%) of patients.
Totals in mutually exclusive categories may not sum to 100 owing to rounding.

b

Available among 7757 Medicaid recipients only for categories as identified.

c

Includes persons with diagnosis of cocaine use disorder and/or amphetaminetype use disorder (including methamphetamine).
JAMA Network Open. 2022;5(5):e2211634. doi:10.1001/jamanetworkopen.2022.11634 (Reprinted)
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0.64 [95% CI, 0.59-0.70]); there was no association between statins and buprenorphine treatment
retention (OR, 0.96 [95% CI, 0.86-1.07]).

Discussion
In this study examining associations between stimulant use and treatment outcomes in persons with
OUD, we had 2 main findings. First, stimulant treatment days were associated with 19% increased

Table 2. Adjusted Odds of Drug-Related Poisoning Associated
With Stimulant Use Among Persons With Opioid Use Disorder
Prescribed Buprenorphine
Medication

OR (95% CI)

Main modela
Stimulant

1.19 (1.06-1.34)

Buprenorphine

0.62 (0.59-0.65)

Benzodiazepine

1.93 (1.84-2.03)

Statin

0.99 (0.86-1.13)

Stratified by timeb,c
January 1, 2006, to May 31, 2013
Stimulant

1.29 (1.09-1.52)

Buprenorphine

0.59 (0.55-0.64)

Benzodiazepine

2.05 (1.92-2.19)

Statin

0.94 (0.79-1.13)

June 1, 2013, to December 31, 2016d
Stimulant

1.13 (0.95-1.35)

Buprenorphine

0.65 (0.60-0.70)

Benzodiazepine

1.78 (1.65-1.92)

Statin

1.00 (0.82-1.23)

Stratified by age
12-29 ye
Stimulant

1.22 (1.04-1.44)

Buprenorphine

0.63 (0.58-0.68)

Benzodiazepine

2.18 (2.01-2.35)

Statin

0.85 (0.42-1.75)

30-64 yf
Stimulant

1.13 (0.94-1.35)

Buprenorphine

0.60 (0.56-0.65)

Benzodiazepine

1.79 (1.68-1.90)

Statin

0.99 (0.87-1.13)

Stimulant prescription during insurance enrollmentg
Stimulant

1.19 (1.05-1.34)

Buprenorphine

0.63 (0.56-0.72)

Benzodiazepine

1.96 (1.75-2.19)

Statin

1.09 (0.75-1.58)

Abbreviation: OR, odds ratio.
a

Includes 22 946 persons (13 778 567 person-days).

b

For time stratification analyses, it was possible that individuals could be
counted twice, given the longitudinal nature of data set.

c

Includes 13 449 persons (6 886 861 person-days).

d

Includes 14 037 persons (6 891 706 person-days).

e

Includes 10 977 persons (6 607 490 person-days).

f

Includes 11 969 persons (7 117 077 person-days).

g

Includes 3628 persons (2 250 582 person-days).
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odds of drug-related poisonings. Second, there was an approximately 36% decreased odds of
attrition from buprenorphine treatment.
Although the risk of drug-related poisoning was modest, clinicians should be cognizant of this
potential safety risk when considering whether to prescribe stimulants to patients with OUD who do
not wish to receive buprenorphine. Interpretation of the observed association between prescription
stimulant use and drug-related poisoning risk deserve careful consideration.
First, previous studies have shown that prescription stimulants are associated with misuse,
even among persons for whom they are prescribed. For example, more than 25% of adolescents who
use stimulants for medical reasons also report misusing their prescription.37 There is also evidence
that almost 20% of college students misuse prescription stimulants36 and more than 30% of adults
who use stimulants misuse them.35 Reasons for misuse are multifactorial and may not necessarily be
related to addiction. For example, common reasons for misuse are to improve concentration35 or
academic performance57,58; however, misuse for these purposes can still increase likelihood of a
negative outcome.
Second, our sample represents a particularly ill subset of the population with OUD: those with a
documented history of drug-related poisoning events. It is a reasonable assumption, then, that our
cohort had a higher likelihood of experiencing negative outcomes with prescription stimulants than a
population who had not previously had a drug-related poisoning. Whether or not our findings are
consistent among a cohort of individuals who have not yet experienced a drug-related poisoning at
the start of the study is an important direction for future research.
Finally, it is possible that the association between stimulant use and drug-related poisoning risk
differs by the indication for which a stimulant is prescribed. Although stimulants are commonly
prescribed for ADHD in adolescents, as many as 50% of stimulant prescriptions are for off-label
indications in the adult population.32 The wide 95% CIs suggesting lack of statistical power limit any
interpretation of potential age differences with respect to stimulant use and drug-related poisoning
risk in our results. Whether the association between stimulant use and drug-related poisoning risk
is different when the stimulant is prescribed for ADHD vs stimulant use disorder or depressive illness
is an important area for future research.
It should be noted that our data provide no insight into the effectiveness of stimulant
medications for treating targeted symptoms (eg, impulsivity associated with ADHD, or anhedonia
associated with depression), nor do they provide information on the risks associated with untreated
symptoms that stimulants may benefit. For example, untreated ADHD has been associated with
higher risks of accidents59 and suicide.60 Clinicians should weigh the risks and benefits of prescribing
stimulants thoughtfully when treating persons with OUD and a co-occurring condition that may
benefit from stimulant treatment.
Importantly, stimulant use was associated with greater duration of buprenorphine treatment.
This finding is consistent with previous work demonstrating stimulants may improve SUD treatment
retention.61 Buprenorphine is a known protective factor against overdose among persons with
OUD,4,25-27 and in our own data set, buprenorphine was associated with a 38% decreased odds of
drug-related poisonings. Given the relatively low retention rates of long-term buprenorphine
use,22,49 the association between stimulant use and increased likelihood of buprenorphine retention
is notable.
Persons prescribed both buprenorphine and stimulants, then, were susceptible to both the risk
(increased per-day overdose odds) and protective (increased buprenorphine exposure) associations
conferred by stimulants. It is therefore important to weigh the magnitude of both of these
associations and how they might be related to net treatment outcomes. Figure 2 provides a visual
interpretation of a potential reconciliation of these opposing results. Extrapolating from our result
that individuals were 36% less likely to cease buprenorphine treatment when using stimulants,
Figure 2 demonstrates that stimulant-involved buprenorphine treatment episodes are approximately
36% longer than treatment episodes for which stimulants are not prescribed. Further, we illustrate
that the increased per-day risk of drug-related poisoning associated with stimulants combined with
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the increased exposure to buprenorphine’s protective effects against overdose results in a net 26%
decreased odds of drug-related poisoning relative to no buprenorphine treatment. This protective
association is similar in magnitude to the risk associated with receipt of buprenorphine without
stimulants, because although the per-day protection associated with buprenorphine without
stimulants is stronger (OR, 0.62), we found that length of the treatment episode in the absence of
stimulants is shorter, resulting in less buprenorphine exposure over time (Figure 2). However, we
cannot rule out certain sources of confounding that may affect our analyses. Regardless, Figure 2
illustrates that both the risks and the benefits of stimulant medication on OUD treatment should be
considered when treating persons with co-occurring OUD and conditions for which stimulants may
be indicated and provides evidence that when buprenorphine is co-prescribed with stimulants to
persons with OUD, they may have comparable protection against overdose over time.

Limitations
This study has some limitations. Case-crossover designs cannot control for time-varying
confounding. We attempted to evaluate for confounding by calendar time by stratifying our sample
by time and found effect sizes were in the same direction for each period examined, although wide
95% CIs preclude definitive interpretation. Another form of time-varying confounding can arise if
within-person exposure and outcome events are not independent. Although it is impossible to
evaluate this assumption, a previous analysis of buprenorphine use in the context of benzodiazepine
use50 found that effect size estimates were robust to selection of time window relative to drugrelated poisoning. It is also important to note that our most recent year of data analyzed was 2016;
given that illicitly manufactured fentanyl did not become the main cause of opioid-related deaths
until after 2015,1 replication of these analyses with more recent data is an important direction of
future research. Pharmacy claims do not always reflect actual consumption of medication; however,
for both buprenorphine and stimulants, proportion of days covered in a treatment episode was high,
suggesting few gaps between refills and providing some evidence of likely consumption. Owing to
the nature of insurance claims data, our study focused on drug-related poisonings that resulted in
emergency department or hospital admissions, although it should be noted that many drug-related
poisonings do not result in health care system contact; therefore, we cannot be certain that the risk
associations we found in our sample generalize to poisonings that do not come to medical attention.
Further, although most drug-related poisonings are not fatal,62 we did not exclude drug-related
poisonings that resulted in death during hospitalization from our outcome definition. Finally, residual
confounding by unmeasured time invariant variables cannot be ruled out.

Figure 2. Illustration of the Net Risk of Drug-Related Poisoning Among Persons With OUD Receiving
Buprenorphine With and Without Co-use of Prescription Stimulants
Without stimulant treatment
Odds of DRP associated with buprenorphine ×
treatment length = (0.62) × (0.64 unit of time) = 0.40

Treatment duration
Buprenorphine treatment days

Odds of DRP associated with no
buprenorphine treatment =
(1.00) × (0.36 unit of time) = 0.36

Net odds of DRP = 0.40 + 0.36 = 0.76

With stimulant treatment
Odds of DRP associated with buprenorphine × odds of DRP associated with stimulants × treatment length =
(0.62) × (1.19) × (1.0 unit of time) = 0.74

Net odds of DRP = 0.74
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Conclusions
The findings of this recurrent-event cohort study with a case-crossover design suggest that stimulant
medication was associated with a modest increased risk of drug-related poisoning among persons
with OUD. However, this risk may be offset by the association between stimulant use and
buprenorphine treatment retention, resulting in prolonged exposure to buprenorphine, which is
associated with protection against overdose.
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